MRNA Latest Press Releases

-- August 28, 2026 --

Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes ACCESS Newswire 7:00 AM

-- August 27, 2026 --

Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines ACCESS Newswire 3:57 PM

Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes ACCESS Newswire 7:20 AM

-- August 26, 2026 --

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer's Biggest Opportunity Globe Newswire 9:20 AM

-- August 19, 2026 --

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma Business Wire 6:45 AM

-- August 5, 2026 --

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA ACCESS Newswire 10:15 PM

-- August 4, 2026 --

Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus ACCESS Newswire 11:00 AM

-- July 31, 2026 --

Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates ACCESS Newswire 7:00 AM

-- July 16, 2026 --

Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors ACCESS Newswire 7:00 AM

-- July 9, 2026 --

Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026 ACCESS Newswire 7:00 AM

-- July 8, 2026 --

Moderna Appoints Michael McDonnell to Board of Directors ACCESS Newswire 7:00 AM

-- June 25, 2026 --

Moderna Science Day Highlights Expanding Potential of mRNA Platform ACCESS Newswire 7:00 AM

-- June 18, 2026 --

Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine ACCESS Newswire 4:00 PM

-- June 17, 2026 --

Moderna to Host Investor Event - Science Day ACCESS Newswire 7:00 AM

-- June 16, 2026 --

Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028 ACCESS Newswire 7:30 AM

-- June 8, 2026 --

Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome ACCESS Newswire 7:01 PM

-- June 3, 2026 --

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion Globe Newswire 8:30 AM

-- June 2, 2026 --

Moderna to Present at Upcoming Conference in June 2026 ACCESS Newswire 7:00 AM

-- June 1, 2026 --

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting ACCESS Newswire 8:00 AM

Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus ACCESS Newswire 5:00 AM

-- May 15, 2026 --

Biologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical Tourism Globe Newswire 10:14 AM

-- May 12, 2026 --

Moderna Recognized by TIME as One of the World's Most Impactful Companies ACCESS Newswire 4:59 PM

-- May 11, 2026 --

CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities Globe Newswire 8:30 AM

-- May 6, 2026 --

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 ACCESS Newswire 5:15 PM

-- May 1, 2026 --

Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates ACCESS Newswire 6:30 AM

-- April 21, 2026 --

Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate ACCESS Newswire 7:01 PM

Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting ACCESS Newswire 10:00 AM

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 ACCESS Newswire 9:40 AM

Moderna to Present at Upcoming Conferences in May 2026 ACCESS Newswire 7:00 AM

-- April 17, 2026 --

Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting ACCESS Newswire 3:00 PM

-- April 15, 2026 --

Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026 ACCESS Newswire 7:00 AM

-- April 6, 2026 --

Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 ACCESS Newswire 6:01 PM